This page describes pharmacological agents that may have legal restrictions, side effects, and drug interactions in your jurisdiction. Information is for educational research only — consult a clinician before considering any compound.
Piracetam
The parent racetam and original nootropic — Corneliu Giurgea synthesized it at UCB Belgium in 1964 and coined the word "nootropic" to…
Aliases (16)
Overview
What is Piracetam?
Piracetam is a pyrrolidinone derivative synthesized in 1964 by UCB Pharma (Belgium), the first compound classified as a "nootropic." It is approved in many European countries for cognitive disorders, myoclonus, and dyslexia, but is unscheduled and unapproved in the US.
Key Benefits
Reported to support cognitive function in aging, post-stroke recovery, dyslexia, and myoclonus. Subjective effects are typically subtle (improved verbal fluency, recall, mental clarity) and require chronic dosing; well-tolerated with very low toxicity profile.
Mechanism of Action
Modulates AMPA glutamate receptors (positive allosteric modulator), enhances acetylcholine release, increases membrane fluidity, and improves cerebral microcirculation. Effects appear to require chronic dosing for full expression.
▸Brand options8 known
Status"**Not FDA-approved as drug or supplement in the US** (FDA: not GRAS, not a recognized dietary ingredient — gray-market research-chem only; Centera Bioscience DOJ enforcement Oct 2023 / Feb 2024 swept piracetam alongside aniracetam/oxiracetam/phenibut/tianeptine). **Prescription medicine in the EU/UK** as Nootropil (UCB Pharma) and many generics — indications include myoclonus (cortical), age-related cognitive decline, post-stroke aphasia (UK), and dyslexia adjunct (some EU markets). **Rx in Australia (S4)**. **OTC in Russia, India, much of Eastern Europe and Latin America.** Not on the WADA prohibited list. Not DEA-scheduled."
Research Indications
Coluracetam
HACU enhancer with reported visual / color enhancement.
Nefiracetam, fasoracetam, brivaracetam, levetiracetam
branched into specific anti-epileptic / anxiolytic / GABA-B niches.
Research Protocols
Disclaimer: These are commonly discussed research protocols and not medical advice.
Peptide Interactions
(already in the user's V stack at 500 mg/day Cognizin) — covers the choline cofactor requirement, prevents headache, supports the cholinergic arm of piraceta…
alternative choline source; some users prefer for racetam stacks due to higher CNS penetration. Citicoline is fine and already in V4. Optional PRN booster (3…
orthogonal mechanism (DAT/NET inhibition + histaminergic for modafinil; AMPA-density + membrane fluidity + cholinergic facilitation for piracetam). No publis…
mitochondrial energy support + acetylcholine precursor; mechanism-aligned with the cholinergic arm. Reasonable PRN combo.
(the user's V stack Carlson Super DHA at 2 g/day) — membrane phospholipid support; theoretically aligns with piracetam's membrane-fluidity mechanism. No docu…
orthogonal mechanism; no documented conflict; theoretical complementarity (acute caffeine + chronic piracetam baseline).
older "cerebrovascular nootropic" pairing in Eastern European clinical practice; theoretical complementarity on the microcirculatory arm.
(aniracetam, oxiracetam, pramiracetam, coluracetam, phenylpiracetam, nefiracetam, fasoracetam) — partial cross-tolerance, additive choline competition, signa…
(warfarin, clopidogrel, high-dose aspirin) — additive bleeding-time prolongation. a user in this archetype is on no anticoagulants; not currently relevant.
discontinue 1-2 weeks before planned procedure if on chronic >4 g/day.
Quality Indicators
Pharmacy-dispensed, intact packaging
Prescription tablets in original sealed packaging from a licensed pharmacy.
Generic vs branded
Generics are usually fine but bioavailability can vary slightly; track if you switch.
Unbranded blister or counterfeit risk
Counterfeit pharmaceuticals are a known issue; verify pharmacy and lot if buying internationally.
What to Expect
- Onset30-90 min. Slower and more gradual than aniracetam (lipophilic, faster) or phenylpiracetam (DA arm, faster perception).
- Peak1.5-3 h. Often imperceptible on first exposure. Many users describe nothing distinguishable from placebo on day 1-3.
Side Effects & Safety
- Common (>10% in trials and biohacker reports):
- Headache (frontal, cholinergic-depletion type) — most common; mitigated by adequate choline cofactor (citicoline 250-500 mg or alpha-GPC 300 mg).
- Mild GI discomfort — nausea, occasional stomach cramps; typically resolves with food.
- Less common (1-10%):
- Insomnia if dosed late-afternoon / evening (rare but reported, especially at high dose).
- Irritability / agitation — uncommon; some users report at high dose (>4.8 g/day).
- Drowsiness (paradoxical) — uncommon but reported in some elderly and clinical populations; not a common healthy-adult report.
- Dizziness / lightheadedness — uncommon.
- Weight gain — reported in some long-term elderly trials (Nootropil pharmacovigilance data); mechanism unclear; not a major signal in healthy-adult use.
- Rare-serious (<1% but worth knowing):
- Bleeding-time prolongation at high doses (>4 g/day chronic). Piracetam's hemorheological mechanism — reduced erythrocyte aggregation, reduced platelet aggregation, lower fibrinogen — translates to mildly increased bleeding tendency at chronic high doses. Clinical relevance: small but non-zero. Discontinue 1-2 weeks before planned surgery or dental procedure. For the user: relevant for MMA contact-sport context only at attack-dose levels; standard maintenance doses (1.6-3.2 g/day) carry minimal practical concern.
- Renal dosing hazard. Half-life jumps from 5 h to 12-50 h in significant renal impairment. Dose-adjust if eGFR <60 mL/min; avoid if eGFR <20. Not relevant for users in this archetype barring an unforeseen finding; check June 2026 bloodwork.
- Hypersensitivity reactions — rash, angioedema in <0.1% of users; standard pharmacovigilance.
- Children with idiopathic generalized epilepsy: rare reports of myoclonic exacerbation. Not relevant for users in this archetype.
- Pregnancy: Category C / B3 in some markets; not adequately characterized; not relevant for users in this archetype.
- Specific watch periods:
- First 1-2 weeks of any new use: monitor for headache (signals choline-cofactor inadequacy) and sleep-onset effects.
- First week of attack-dose protocol (if used): monitor for irritability, headache, GI tolerance — back off if any clear signal emerges.
- Chronic >12 months: essentially no novel safety concern in the published clinical literature; renal function check annually if combining with any other renal-cleared drug.
- Pre-surgical / pre-dental periods: discontinue 1-2 weeks prior if running chronic high dose (>4 g/day).
References
Piracetam — Wikipedia
chemical identity (CAS 7491-74-9), brand names, regulatory status by country, metabolism summary, pharmacokinetics summary.
View StudyMalykh & Sadaie (2010) — "Piracetam and piracetam-like drugs" (*Drugs*)
comprehensive review; A-tier signal in vascular CI / post-stroke aphasia / myoclonus; healthy-adult cognitive-enhancement signal weak and inconsistent.
View StudyFlicker & Grimley Evans (2001, updated) — Piracetam for dementia or cognitive impairment (Cochrane)
Cochrane review supporting modest benefit on global clinical impression in cognitive impairment; basis for EU clinical use.
View StudyWaegemans et al. (2002) — Clinical efficacy of piracetam in cognitive impairment: meta-analysis (*Dementia Geriatr Cogn Disord*)
meta-analytic confirmation of CIBIC-positive signal; n>4,000.
View StudyWilsher et al. (1987) — Piracetam and dyslexia (*J Clin Psychopharmacol*)
RCT of 3.3 g/day in dyslexic children; positive on reading endpoints.
View StudyAhmed & Oswald (2010) — Piracetam defines a new binding site for AMPA allosteric modulators (*J Med Chem*)
co-crystallization paper establishing the AMPA-binding-site-density mechanism distinct from classical PAM site.
View StudySpignoli & Pepeu (1987) — Effect of oxiracetam and piracetam on central cholinergic mechanisms (PubMed 3594455)
facilitate-when-active cholinergic mechanism.
View StudyMüller, Eckert, Eckert (1999) — Piracetam: novelty in mechanism of action; membrane-fluidity restoration in aged neurons
mechanism paper for the age-restricted membrane-fluidity arm.
View StudyPeuvot, Schanck, Briasco, Brasseur (1995) — Piracetam membrane interaction; phospholipid bilayer effects
biophysical characterization of piracetam-phospholipid interaction.
View StudyGiurgea (1972) — Pharmacology of integrative activity of the brain; nootropic concept
original Giurgea paper coining "nootropic."
View StudyHuber et al. (1997) — Piracetam in post-stroke aphasia
post-stroke aphasia RCT supporting EU indication.
View StudyEnderby & Broeckx (1994) — Piracetam in post-stroke aphasia
additional post-stroke aphasia trial.
View StudyCroisile et al. (1993) — Long-term high-dose piracetam in Alzheimer's disease (*Neurology*)
AD trial; mixed results.
View StudyDonma (2010) — Piracetam in pediatric breath-holding spells
pediatric breath-holding indication.
View StudySun et al. (2024) — Pharmacological treatments for vascular dementia: Bayesian network meta-analysis (*Frontiers in Pharmacology*)
modern meta-analysis ranking racetams below butylphthalide / huperzine A / donepezil / edaravone for cognitive endpoints.
View StudyNootropil (UCB Pharma) UK Summary of Product Characteristics
EU prescription label; indications include myoclonus, age-related cognitive decline, post-stroke aphasia.
View StudyPsychonautWiki — Piracetam
biohacker-corpus reference; subjective effects, dosing tiers, tolerance kinetics.
View StudyNootropics Expert — Piracetam
secondary biohacker source; dosing guidance, choline cofactor stack rationale, side effects.
View StudyArizona Company and CEO Sentenced for Illegal Distribution of Tianeptine and Other Drugs (FDA / DOJ press release, Feb 2024)
Centera Bioscience / Nootropics Depot DOJ case; piracetam swept alongside aniracetam/oxiracetam/phenibut/tianeptine.
View StudyNCATS Inxight Drugs — Piracetam (ZH516LNZ10)
regulatory database entry; US: unapproved drug; EU: prescription.
View StudyHow was your experience with this compound?
Anonymous · one vote per session · results below at 5+ votes.
See something off?
Most of this wiki is AI-generated. Suggest a correction, dosing update, or new evidence — we review every submission.